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Abstract
Background: Polymorphisms in the CYP1A2 genes have the potential to affect the individual capacity to convert
pre-carcinogens into carcinogens. With these comprehensive meta-analyses, we aimed to provide a quantitative
assessment of the association between the published genetic association studies on CYP1A2 single nucleotide
polymorphisms (SNPs) and the risk of cancer.
Methods: We searched MEDLINE, ISI Web of Science and SCOPUS bibliographic online databases and databases of
genome-wide association studies (GWAS). After data extraction, we calculated Odds Ratios (ORs) and 95 %
confidence intervals (CIs) for the association between the retrieved CYP1A2 SNPs and cancer. Random effect model
was used to calculate the pooled ORs. Begg and Egger tests, one-way sensitivity analysis were performed, when
appropriate. We conducted stratified analyses by study design, sample size, ethnicity and tumour site.
Results: Seventy case-control studies and one GWA study detailing on six different SNPs were included. Among
the 71 included studies, 42 were population-based case-control studies, 28 hospital-based case-control studies and
one genome-wide association study, including total of 47,413 cancer cases and 58,546 controls. The meta-analysis
of 62 studies on rs762551, reported an OR of 1.03 (95 % CI, 0.96–1.12) for overall cancer (P for heterogeneity < 0.01;
I2 = 50.4 %). When stratifying for tumour site, an OR of 0.84 (95 % CI, 0.70–1.01; P for heterogeneity = 0.23, I2 = 28.5 %)
was reported for bladder cancer for those homozygous mutant of rs762551. An OR of 0.79 (95 % CI, 0.65–0.95; P for
heterogeneity = 0.09, I2 = 58.1 %) was obtained for the bladder cancer from the hospital-based studies and on
Caucasians.
Conclusions: This large meta-analysis suggests no significant effect of the investigated CYP1A2 SNPs on cancer overall
risk under various genetic models. However, when stratifying according to the tumour site, our results showed a
borderline not significant OR of 0.84 (95 % CI, 0.70–1.01) for bladder cancer for those homozygous mutant of rs762551.
Due to the limitations of our meta-analyses, the results should be interpreted with attention and need to be further
confirmed by high-quality studies, for all the potential CYP1A2 SNPs.
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Background
Cancer is a complex disease that develops as a result of
the interactions between environmental factors and gen-
etic inheritance. In 2012 there were 14.1 million new
cancer cases and 8.2 million cancer deaths worldwide
[1]. Endogenous or exogenous xenobiotics are activated
or inactivated through two metabolic steps by phase I
and phase II enzymes [2]. The majority of chemical car-
cinogens require activation to electrophilic reactive
forms to produce DNA adducts and this is mainly cata-
lyzed by phase I enzymes. Although there are some ex-
ceptions, phase II enzymes, in contrast, detoxify such
intermediates through conjugative reactions. The conse-
quent formation of reactive metabolites and their bind-
ing to DNA to give stable adducts are considered to be
critical in the carcinogenic process. It might therefore be
expected that individuals with increased activation or
low detoxifying potential have a higher susceptibility for
cancer [3].
Cytochrome P450 1A2 (CYP1A2) enzyme is a member
of the cytochrome P450 oxidase system and is involved
in the phase I metabolism of xenobiotics. In humans,
the CYP1A2 enzyme is encoded by the CYP1A2 gene
[4]. In vivo, CYP1A2 activity exhibits a remarkable de-
gree of interindividual variations, as the gene expression
is highly inducible by a number of dietary and environ-
mental chemicals, including tobacco smoking, hetero-
cyclic amines (HAs), coffee and cruciferous vegetables.
Another possible contributor to interindividual variabil-
ity in CYP1A2 activity is the occurrence of polymor-
phisms in the CYP1A2 gene [5], which have the
potential for determining individual’s different suscepti-
bility to carcinogenesis [6]. CYP1A2 is expressed mainly
in the liver, but also, expression of the CYP1A2 enzyme
in pancreas and lung has been detected. The CYP1A2
gene consists of 7 exons and is located at chromosome
15q22-qter. More than 40 single nucleotide polymor-
phisms (SNPs) of the CYP1A2 gene have been discov-
ered so far [7, 8].
High in vivo CYP1A2 activity has been suggested to be
a susceptibility factor for cancers of the bladder, colon and
rectum, where exposure to compounds such as aromatic
amines and HAs has been implicated in the etiology of
the disease [5, 6]. Additionally, it has been reported that
among the CYP1A2 polymorphisms, CYP1A2*1C
(rs2069514) and CYP1A2*1 F (rs762551) are associated
with reduced enzyme activity in smokers [5].
In recent years, efforts have been put into investi-
gating the association of CYP1A2 polymorphisms and
the risk of several cancers, among them, colorectal
[9–23], lung [7, 24–32], breast [33–46], bladder [4,
47–52], and other in different population groups, with
inconsistent results. Therefore, with these meta-
analyses we aimed to provide a quantitative
assessment of the association between all CYP1A2
polymorphisms and risk of cancer at various sites.
Methods
Selection criteria
Identification of the studies was carried out through a
search of MEDLINE, ISI Web of Science and SCOPUS
databases up to February 15th, 2015, by two independent
researchers (R.A. and V.V.). The following terms were
used: [(Cytochrome P450 1A2) OR (CYP1A2)] AND
(Cancer) AND (Humans [MeSH]), without any restric-
tion on language. All eligible studies were retrieved, and
their bibliographies were hand-searched to find add-
itional eligible studies. We only included published stud-
ies with full-text articles available.
Also, detail search of several publically available data-
bases of genome-wide association studies (GWAS) -
GWAS Central, Genetic Associations and Mechanisms
in Oncology (GAME-ON), the Human Genome Epi-
demiology (HuGE) Navigator, National Human Genome
Research Institute (NHGRI GWAS Catalog), The data-
base of Genotypes and Phenotypes (dbGaP), The
GWASdb, VarySysDB Disease Edition (VaDE), The gen-
ome wide association database (GWAS DB), was carried
out up to February 15th, 2015 for the association be-
tween CYP1A2 and various cancers using the combina-
tions of following terms: (Cytochrome P450 1A2) OR
(CYP1A2) OR (Chromosome 15q24.1) AND (Cancer).
Additional consultation of principal investigators (PI) of
the retrieved GWAS was undertaken in order to obtain
the primary data and include them in the analyses.
Studies were considered eligible if they were assessing
the frequency of any CYP1A2 gene polymorphism in re-
lation to the number of cancer cases and controls, ac-
cording to the three variant genotypes (wild-type
homozygous (wtwt), heterozygous (wtmt) and homozy-
gous mutant (mtmt)). Case-only and case series studies
with no control population were excluded, as well as
studies based only on phenotypic tests, reviews, meta-
analysis and studies focused entirely on individuals
younger than 16 years old. When the same sample was
used in several publications, we only considered the
most recent or complete study to be used in our meta-
analyses. Meanwhile, for studies that investigated more
types of cancer, we counted them as individual data only
in a subgroup analysis by the tumour type, while when
they reported different ethnicity or location within the
same study, we considered them as a separate studies.
Data extraction
Two investigators (C.I. and V.V.) independently ex-
tracted the data from each article using a structured
sheet and entered them into the database. The following
items were considered: rs number, first author, year and
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location of the study, tumour site, ethnicity, study de-
sign, number of cases and controls, number of heterozy-
gous and homozygous individuals for the CYP1A2
polymorphisms in the compared groups. We used widely
accepted National Center for Biotechnology Information
(NCBI) CYP classification [53] to determine which spe-
cific genotype should be considered as wtwt, wtmt and
mtmt. We also ranked studies according to their sample
size, where studies with minimum of 200 cases were
classified as small and above 200 cases as large.
Statistical analysis
The estimated Odds Ratios (ORs) and 95 % confidence
interval (CI) for the association between each CYP1A2
SNP and cancer were defined as follows:
 wtmt vs wtwt (OR1)
 mtmt vs wtwt (OR2).
According to the following algorithm on the criteria to
identify the best genetic model [54] for each SNP:
 Recessive model (mtmt versus wt carriers): if OR2 ≠
1 and OR1 = 1
 Dominant model (mt carriers versus wtwt): if OR2 =
OR1 ≠ 1,
we used the dominant model of inheritance for
rs2069514, rs2069526 and rs35694136 and recessive
model for rs762551, rs2470890 and rs2472304 in the
meta-analysis. Random effect model was used to calcu-
late the pooled ORs, taking into account the possibility
of between studies heterogeneity [55], that was evaluated
by the χ2-based Q statistics and the I2 statistics [56],
where I2 = 0 % indicates no observed heterogeneity,
within 25 % regarded as low, 50 % as moderate, and
75 % as high [57]. A visual inspection of Begg’s funnel
plot and Begg’s and Egger’s asymmetry tests [58] were
used to investigate publication bias, where appropriate
[59]. To determinate the deviation from the Hardy-
Weinberg Equilibrium (HWE) we used a publicly avail-
able program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl ).
Additionally, the Galbraith’s test [60] was performed to
evaluate the weight each study had on the overall esti-
mate and its contribution on Q-statistics. We also per-
formed a one-way sensitivity analysis to explore the
effect that each study had on the overall effect estimate,
by computing the meta-analysis estimates repeatedly
after every study has been omitted.
Studies whose allele frequency in the control popula-
tion deviated significantly from the Hardy-Weinberg
Equilibrium (HWE) at the p-value ≤ 0.01 were excluded
from the meta-analyses, given that this deviation may
represent bias. We conducted stratified analysis by study
design, ethnicity, sample size and tumour site to investi-
gate the potential sources of heterogeneity across the
studies. Statistical analyses were performed using the
STATA software package v. 13 (Stata Corporation, Col-
lege 162 Station, TX, USA), and all statistical tests were
two-sided.
Results
Characteristics of the studies
We identified a total of 2541 studies through MEDLINE,
ISI Web of Science and SCOPUS online databases. One
thousand and sixteen studies were left after duplicates
removal, and after carefully reading the titles, only 175
studies were assessed for eligibility. After reviewing the
abstracts, 120 full text articles were obtained for further
eligibility. By not fulfilling the inclusion criteria, 61 full
text articles were excluded, leaving 59 studies for quanti-
tative synthesis. Additional hand-search of the reference
lists of 59 included studies was done and 11 new eligible
studies were found, resulting in 70 included studies.
Eleven GWASs on the association between CYP1A2
SNPs and cancer risk were identified after detail search
of GWAS online databases. Studies did not report full
data on investigated SNPs, so we contacted principal in-
vestigators (PIs) to retrieve the information and include
into our analyses. After 3 repeated solicitations, only one
PI provided us with the full data on CYP1A2 SNPs of
breast cancer cases and controls, and by this making
total of 71 studies included in our meta-analyses [4, 7–
52, 61–84]. Figure 1 shows the process of literature
search and study selection.
Among the 71 included studies, 42 were population-
based case-control studies, 28 hospital-based case-
control studies and one genome-wide association study,
including total of 47,413 cancer cases and 58,546 con-
trols (Table 1). The total investigated SNPs were six, of
which 62 studies on the rs762551 [4, 7–21, 23, 24, 26–
46, 48–50, 52, 61–65, 67, 68, 72–75, 77–79, 81–84].
Thirty five studies out of 62 were conducted on Cauca-
sians (56.5 %), 17 on mixed populations (27.4 %) and 10
on Asians (16.1 %), including 33,181 cancer cases and
40,195 controls. Among them, 15 were on breast cancer,
14 studies on colorectal, and 9 on lung cancer.
Twenty studies investigated the rs2069514 [9, 16, 18,
22–27, 29–32, 34, 47, 51, 61, 66, 71, 76], of which 11
were conducted on Caucasians (55 %) and 9 on Asians
(45 %). Eight studies investigated the effect on lung can-
cer (40 %), 5 studies on colorectal cancer (25 %), 2 on
liver cancer (10 %), 2 on bladder (10 %) and by 1 study
on stomach (5 %), breast (5 %) and pleura (5 %), totaling
for 4562 cancer cases and 6399 controls (Table 1).
The remaining four SNPs were investigated by a re-
duced number of studies and details are presented in
Table 1. Genotype frequencies in all control groups did
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not deviate from values predicted by HWE (Table 1). As
some studies on different cancer types shared the same
control group [35], these studies were aggregated when
performing the meta-analyses, except when stratified by
tumour site.
Quantitative synthesis
As the crude analysis for rs762551 provided an OR1 of
1.03 (95 % CI 0.98–1.07) and an OR2 of 1.06 (95 % CI
0.97–1.16), for rs2470890 OR1 1.03 (95 % CI 0.93–1.14)
and OR2 of 1.14 (95 % CI 0.97–1.34) and for rs2472304
OR1 of 0.98 (95 % CI 0.79–1.22) and OR2 of 0.89 (95 %
CI 0.66–1.22) according to the criteria proposed in the
methods section, we applied the recessive model of in-
heritance for the meta-analyses. On the other hand, for
rs2069514, rs2069526 and rs35694136 original papers
did not report enough data to calculate OR1 and OR2,
so we were able only to apply the dominant model for
the data analyses.
The Figs. 2 and 3 depict the forest plots of the ORs of
the six CYP1A2 SNPs and cancer. By pooling 62 studies
on rs762551, the meta-analysis reported an OR of 1.03
(95 % CI 0.96–1.12) for overall cancer (P for heterogen-
eity < 0.01; I2 = 50.4 %). Egger test and the Begg’s correl-
ation method did not provide statistical evidence of
publication bias (P = 0.19 and P = 0.39, respectively)
(Fig. 4). To explore the potential sources of heterogen-
eity, we performed the Galbraith’s test which identified
the study of Shimada N. (b) [45] and Sangrajrang S. [44],
as the main contributors to heterogeneity (graph not
shown). In the one-way sensitivity analysis, these two
outlying studies were omitted from meta-analysis and
Fig. 1 Flowchart depicting literature search and study selection. *GWAS data bases searched: GWAS Central, Genetic Associations and
Mechanisms in Oncology (GAME-ON), the Human Genome Epidemiology (HuGE) Navigator, National Human Genome Research Institute (NHGRI
GWAS Catalog), The database of Genotypes and Phenotypes (dbGaP), The GWASdb, VarySysDB Disease Edition (VaDE), The genome wide
association database (GWAS DB)
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Table 1 Description of 45 studies included in meta-analysis of association between different CYP1A2 SNPs and cancer
Rs number First author Year Tumour site Country Ethnicity Sample size
(No. cases/controls)
Crude OR° (95 % CI)
recessive model
Crude OR
(95 % CI)
dominant model
rs762551 Goodman MT. [73] 2001 Ovaries USA Mixed 116/138*a 0.52 (0.19–1.43) –
Sachse C. [18] 2002 Colorectum UK Caucasian 490/593*ª 1.15 (0.70–1.88) –
Goodman MT. [74] 2003 Ovaries USA Mixed 164/194*ª 0.73 (0.34–1.55) –
Hopper J. [36] 2003 Breast Australia Caucasian 204/287*c 0.55 (0.27–1.13) –
Doherty JA. [68] 2005 Endometrium USA Mixed 371/420*ª 1.27 (0.75–2.15) –
Landi S. [16] 2005 Colorectum Spain Caucasian 361/321*b 1.74 (1.05–2.88) –
Le Marchand L.
[39]
2005 Breast USA Mixed 1339/1369*a 0.73 (0.55–0.96) –
Prawan A. [81] 2005 Liver Thailand Asian 216/233*a 0.52 (0.24–1.13) –
Mochizuki J. [79] 2005 Liver Japan Asian 31/123*a 1.35 (0.26–7.01) –
Agudo A. [61] 2006 Stomach European
countries1
Caucasian 242/943*a 0.88 (0.50–1.55) –
Bae SY. [9] 2006 Colorectum S. Korea Asian 111/93*b 1.14 (0.51–2.54) –
De Roos AJ. [67] 2006 Lymphoma USA Mixed 745/640*a 0.91 (0.63–1.31) –
Li D. [8] 2006 Pancreas USA Mixed 307/333*b 1.10 (0.65–1.84) –
Long JR. [41] 2006 Breast China Asian 1082/1139*a 0.89 (0.71–1.13) –
Rebbeck TR [82] 2006 Endometrium USA Mixed 475/1233*a 1.03 (0.73–1.46) –
Kiss I. [13] 2007 Colorectum Hungary Caucasian 500/500*b 1.07 (0.74–1.54) –
Kury S. [15] 2007 Colorectum France Caucasian 1013/1118*a 1.03 (0.75–1.41) –
Osawa Y. [29] 2007 Lung Japan Asian 103/111*a 1.17 (0.57–2.42) –
Takata Y. [46] 2007 Breast USA (Hawaii) Mixed 325/250*a 0.76 (0.39–1.49) –
Yoshida K. [23] 2007 Colorectum Japan Asian 64/111*a 0.57 (0.21–1.53) –
Gemignani F. [26] 2007 Lung European
countries2
Caucasian 297/310*b 0.86 (0.50–1.49) –
Kotsopoulos J. [38] 2007 Breast Canada Caucasian 170/241*b 2.12 (0.99–4.57) –
Gulyaeva LF. [35] 2008 Endometrium Russia Caucasian 166/180*a 2.20 (0.40–12.16) –
Gulyaeva LF. [35] 2008 Ovaries Russia Caucasian 96/180*a 9.21 (1.95–43.53) –
Gulyaeva LF. [35] 2008 Breast Russia Caucasian 93/180*a 27.58
(6.32–120.35)
–
Hirata H. [75] 2008 Endometrium USA Caucasian 150/165*a 0.96 (0.62–1.51) –
Saebo M. [19] 2008 Colorectum Norway Caucasian 198/222*a 1.05 (0.49–2.23) –
Suzuki H. [84] 2008 Pancreas USA Caucasian 649/585*a 0.93 (0.56–1.54) –
Figueroa JD [48] 2008 Bladder Spain Caucasian 1101/1021*b 0.80 (0.62–1.04) –
Zienolddiny S. [32] 2008 Lung Norway Caucasian 335/393*a 1.43 (0.88–2.32) –
Cotterchio M. [11] 2008 Colorectum Canada Caucasian 835/1247*a 0.91 (0.67–1.23) –
Aldrich MC. [7] 2009 Lung USA Mixed 113/299*a 3.36 (1.58–7.13) –
Altayli E. [4] 2009 Bladder Turkey Caucasian 135/128*b 1.51 (0.88–2.60) –
B’chir F. [24] 2009 Lung Tunisia Caucasian 101/98*b 0.90 (0.47–1.70) –
Kobayashi M. [78] 2009 Stomach Japan Asian 141/286*b 0.62 (0.33–1.18) –
Kobayashi M. [14] 2009 Colorectum Japan Asian 104/225*b 0.64 (0.31–1.32) –
Shimada N (a) [45] 2009 Breast Japan and
Brazil
Asian 483/484*b 1.02 (0.71–1.47) –
Shimada N (b) [45] 2009 Breast Brazil Mixed 389/389*b 0.50 (0.31–0.80) –
Sangrajrang S. [44] 2009 Breast Thailand Asian 552/483*b 2.72 (1.52–4.86) –
Villanueva C. [52] 2009 Bladder Spain Caucasian 1034/911*b 0.82 (0.62–1.07) –
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Table 1 Description of 45 studies included in meta-analysis of association between different CYP1A2 SNPs and cancer (Continued)
Canova C. [64] 2009 UADT European
countries3
Caucasian 1480/1437*b 0.88 (0.69–1.13) –
Cleary SP [10] 2010 Colorectum Canada Caucasian 1165/1290*a 0.93 (0.71–1.22) –
Pavanello S. [50] 2010 Bladder Italy Caucasian 155/161*b 0.57 (0.25–1.30) –
Singh A. [31] 2010 Lung India Caucasian 200/200*a 0.61 (0.37–1.00) –
The MARIE-GENICA
Consortium [43]
2010 Breast Germany Caucasian 3147/5485*a 1.04 (0.88–1.22) –
Canova C. [65] 2010 UADT Italy Caucasian 376/386*b 1.21 (0.77–1.89) –
Ashton KA [62] 2010 Endometrium Australia Caucasian 191/291*a 1.03 (0.71–1.49) –
Guey LT [49] 2010 Bladder Spain Caucasian 1005/1021*b 0.77 (0.58–1.00) –
Rudolph A. [17] 2011 Colorectum Germany Caucasian 678/680*a 1.38 (0.93–2.05) –
Sainz J. [20] 2011 Colorectum Germany Caucasian 1764/1786*a 0.95 (0.75–1.19) –
Jang JH [77] 2012 Pancreas Canada Mixed 447/880*a 1.08 (0.73–1.59) –
Khvostova EP [37] 2012 Breast Russia Caucasian 323/526*b 1.82 (1.14–2.90) –
Pavanello S. [30] 2012 Lung Denmark Caucasian 421/776*a 1.63 (1.08–2.48) –
Wang J. [21] 2012 Colorectum USA Mixed 305/357*a 0.97 (0.55–1.70) –
Anderson LN [33] 2012 Breast Canada Mixed 886/932*a 1.50 (1.09–2.07) –
Ayari I. [34] 2013 Breast Tunisia Caucasian 117/42*b 1.62 (0.51–5.11) –
Barbieri RB [63] 2013 Thyroid gland Brasil Mixed 123/339*a 2.12 (1.16–3.87) –
Dik VK [12] 2013 Colorectum The
Netherlands
Caucasian 970/1590*a 1.10 (0.85–1.43) –
Gervasini G. [27] 2013 Lung Spain Caucasian 95/196*b 1.25 (0.60–2.61) –
Lee HJ. [40] 2013 Breast USA Mixed 579/981*a 1.22 (0.85–1.75) –
Lowcock E. [42] 2013 Breast Canada Mixed 1693/1761*a 1.24 (0.97–1.57) –
Ghoshal U. [72] 2014 Stomach India Caucasian 88/170*a 1.13 (0.57–2.22) –
Mikhalenko AP.
[28]
2014 Lung Belarus Caucasian 92/328*a 1.14 (0.44–2.93) –
Shahabi A. [83] 2014 Prostate USA Mixed 1480/777*a 0.97 (0.72–1.30) –
rs2069514 Sachse C. [18] 2002 Colorectum UK Caucasian 60/73*a – 12.71
(1.56–103.44)
Tsukino H. [51] 2004 Bladder Japan Asian 306/306*a – 0.95 (0.69–1.31)
Landi S. [16] 2005 Colorectum Spain Caucasian 328/295*b – 0.90 (0.38–2.10)
Chiou HL [25] 2005 Lung China Asian 162/208*b – 1.04 (0.69–1.57)
Agudo A. [61] 2006 Stomach European
countries1
Caucasian 243/945*a – 1.66 (0.72–3.84)
Chen X. [66] 2006 Liver China Asian 430/546*a – 0.97 (0.75–1.24)
Bae SY. [9] 2006 Colorectum S. Korea Asian 111/93*b – 0.68 (0.39–1.18)
Yoshida K. [23] 2007 Colorectum Japan Asian 66/113*a – 0.82 (0.44–1.52)
Osawa Y. [29] 2007 Lung Japan Asian 106/113*a – 0.80 (0.46–1.36)
Gemignani F. [26] 2007 Lung European
countries2
Caucasian 278/294*b – 0.52 (0.16–1.75)
Zienolddiny S. [32] 2008 Lung Norway Caucasian 243/214*a – 0.65 (0.22–1.91)
Imaizumi T. [76] 2009 Liver Japan Asian 209/256*a – 0.88 (0.61–1.27)
B’chir F. [24] 2009 Lung Tunisia Caucasian 101/98*b – 5.88
(2.96–11.70)
Yeh CC [22] 2009 Colorectum Taiwan Asian 718/731*b – 1.08 (0.88–1.32)
Gemignani F. [71] 2009 Pleura Italy Caucasian 92/643*b – 0.33 (0.04–2.45)
Singh A. [31] 2010 Lung India Caucasian 200/200*a – 0.84 (0.47–1.50)
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the overall OR slightly changed to 1.03 (95 % CI 0.96–
1.11), with a reduced heterogeneity (P for heterogeneity
<0.01; I2 = 43.0 %).
Results of the stratified meta-analyses are reported in
the Table 2. When stratifying the results of meta-analysis
for rs762551 by ethnicity, we found no significant effect
of CYP1A2 on cancer risk for Caucasians (OR = 1.03;
95 % CI 0.94–1.13), Asians (OR = 0.95; 95 % CI 0.72–
1.27) nor among a mixed population (OR = 1.05; 95 %
CI 0.89–1.25). When stratifying according to the tumour
site, results showed an OR of 0.84 (95 % CI 0.70–1.01; P
for heterogeneity = 0.23, I2 = 28.5 %) for bladder cancer
for those homozygous mutant types of rs762551
(Table 2). We further examined the association between
Table 1 Description of 45 studies included in meta-analysis of association between different CYP1A2 SNPs and cancer (Continued)
Pavanello S. [30] 2012 Lung Denmark Caucasian 423/777*a – 0.85 (0.32–2.24)
Ayari I. [34] 2013 Breast Tunisia Caucasian 109/41*b – 0.35
(0.14–0.90)
Gervasini G. [27] 2013 Lung Spain Caucasian 95/196*b – 2.67 (0.70–10.17)
Cui X. [47] 2013 Bladder Japan Asian 282/257*b – 0.89 (0.63–1.26)
rs2069526 Sachse C. [18] 2002 Colorectum UK Caucasian 490/593*a – 0.86 (0.60–1.22)
Landi S. [16] 2005 Colorectum Spain Caucasian 321/288*b – 1.27 (0.55–2.90)
Gemignani F. [26] 2007 Lung European
countries2
Caucasian 247/251*b – 0.34
(0.14–0.81)
Zienolddiny S. [32] 2008 Lung Norway Caucasian 194/239*a – 1.66 (0.37–7.49)
Gemignani F. [71] 2009 Pleura Italy Caucasian 78/579*b – 1.10 (0.42–2.90)
Singh A. [31] 2010 Lung India Caucasian 200/200*a – 1.07 (0.65–1.75)
Gervasini G. [27] 2013 Lung Spain Caucasian 95/196*b – 1.36 (0.57–3.27)
rs2470890 Hopper J. [36] 2003 Breast Australia Caucasian 204/287*c 0.82 (0.47–1.43) –
Landi S. [16] 2005 Colorectum Spain Caucasian 353/320*b 1.24 (0.84–1.82) –
Chen X. [66] 2006 Liver China Asian 428/545*a 0.53 (0.27–1.06) –
Kury S. [15] 2007 Colorectum France Caucasian 1013/1118*a 1.07 (0.90–1.27) –
Gemignani F. [26] 2007 Lung European
countries2
Caucasian 283/298*b 0.83 (0.51–1.35) –
Aldrich MC. [7] 2009 Lung USA Mixed 113/299*a 1.12 (0.59–2.13) –
Gemignani F. [71] 2009 Pleura Italy Caucasian 85/669*b 1.02 (0.56–1.88) –
Canova C. [64] 2009 UADT European
countries3
Caucasian 1455/1403*b 1.03 (0.84–1.26) –
Canova C. [65] 2010 UADT Italy Caucasian 374/387*b 1.51 (1.02–2.23) –
Anderson LN [33] 2012 Breast Canada Mixed 884/927*a 1.49 (1.18–1.89) –
Eom SY. [69] 2013 Stomach S. Korea Asian 473/472*b 1.15 (0.55–2.37) –
rs2472304 Hopper J. [36] 2003 Breast Australia Caucasian 204/286*c 0.81 (0.46–1.43) –
Sangrajrang S. [44] 2009 Breast Thailand Asian 552/478*b 1.16 (0.59–2.29) –
Aldrich MC. [7] 2009 Lung USA Mixed 112/297*a 1.12 (0.59–2.14) –
Ferlin A. [70] 2010 Testicles Italy Caucasian 234/218*a 0.68 (0.46–1.01) –
rs35694136 Li D. [8] 2006 Pancreas USA Mixed 307/329*b – 0.87 (0.63–1.18)
Olivieri EH [80] 2009 Head and
Neck
Brasil Mixed 81/134*b – 8.98
(4.49–17.93)
Pavanello S. [50] 2010 Bladder Italy Caucasian 167/141*b – 0.73 (0.46–1.14)
Singh A. [31] 2010 Lung India Caucasian 200/200*a – 1.65
(1.11–2.45)
Pavanello S. [30] 2012 Lung Denmark Caucasian 415/760*a – 0.98 (0.65–1.49)
Ayari I. [34] 2013 Breast Tunisia Caucasian 108/38*b – 0.88 (0.40–1.93)
Statistically significant results are presented in bold. °OR (95 % CI) Odds Ratio and 95 % Confidence Interval 1Ten European countries: Denmark, France, Germany,
Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. 2Six European countries: Romania, Hungary, Poland, Russia, Slovakia, Czech
Republic. 3Ten European countries: Czech Republic, Germany, Greece, Italy, Ireland, Norway, United Kingdom, Spain, Croatia, France. *Hardy-Weinberg Equilibrium
(HWE), P value ˃0.01. aPopulation-based study bHospital-based study cGenome-wide Association Study. (a), (b) One study with two different population
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the CYP1A2 polymorphism and cancer risk according to
ethnicity, source of controls and sample size and then
stratified by cancer type. We found a significant OR of
0.79 (95 % CI 0.65–0.95; P for heterogeneity = 0.09, I2 =
58.1 %) for bladder cancer among the hospital-based
population and among Caucasians. There was no signifi-
cant association among Caucasians for breast cancer
(OR = 1.71; 95 % CI 0.94–3.10; P for heterogeneity < 0.01,
I2 = 83.4 %), lung cancer (OR = 1.07; 95 % CI 0.79–1.44; P
for heterogeneity = 0.07, I2 = 48.1 %,) or colorectal cancer
(OR = 1.05, 95 % CI 0.94–1.16; P for heterogeneity = 0.49,
I2 = 0.0 %). Among Asians, when stratifying for cancer
type, we obtained an OR of 0.76 (95 % CI 0.47–1.22; P for
heterogeneity = 0.48, I2 = 0.0 %) for colorectal cancer and
OR = 1.27 (95 % CI 0.75–2.16; P for heterogeneity <0.01,
I2 = 83.6 %) for breast cancer.
When pooling the 20 studies on rs2069514, the meta-
analysis provided an OR of 0.99 (95 % CI 0.81–1.21) for
overall cancer (P for heterogeneity <0.01; I2 = 60 %)
(Fig. 2). Egger test and the Begg’s correlation method
provided no statistical evidence of publication bias (P =
0.86 and P = 0.56, respectively). We performed the Gal-
braith’s test to explore the source of heterogeneity and
accordingly singled out the study of B’chir F. et al. [24]
as the main contributor to heterogeneity (graph not
shown). In the one-way sensitivity analysis, the study of
B’chir F. et al. [24] was omitted from the overall
meta-analysis and the heterogeneity dropped down to
14 % (P = 0.28), with the OR of 0.93 (95 % CI 0.82–1.06).
We evaluated the effect of the rs2069514 polymorphism
according to the tumour site and obtained an OR of 0.96
(95 % CI 0.65–1.43; P for heterogeneity = 0.07, I2 = 53.2 %)
Fig. 2 Forest plot of the CYP1A2 rs762551 and cancer meta-analysis under recessive models of inheritance. The diamonds and horizontal lines
correspond to the study-specific odds ratio (OR) and 95 % confidence interval (CI)
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for colorectal cancer, an OR of 1.29 (95 % CI 0.60–2.79; P
for heterogeneity = 0.00; I2 = 82.1 %) for lung cancer
(Table 2). Analyses on different ethnicity and study design
did not provide any significant results (Caucasians OR =
1.16; 95 % CI 0.63–2.14; I2 = 75.7 %, P < 0.01, for Asians
OR = 0.96; 95 % CI 0.86–1.07, I2 = 0.0 %; P = 0.86 and
Hospital-based study design OR = 1.01; 95 % CI 0.73–
1.40; I2 = 73.7 %, P < 0.01, for Population-based design OR
= 0.94; 95 % CI 0.78–1.14; I2 = 10.6 %, P = 0.35). We did
not observe any significant association between rs2069514
polymorphism and cancer risk when subgrouping data ac-
cording to ethnicity, source of controls and sample size
and then stratified by cancer type. Among Caucasians,
we obtained an OR of 1.28 (95 % CI 0.55–2.98; I2 =
80.9 %, P < 0.01) for lung cancer, while among Asians
OR = 0.94 (95 % CI 0.68–1.31; I2 = 0.0 %, P = 0.44) for
lung and OR = 0.94 (95 % CI 0.71–1.24; I2 = 28.8 %, P
= 0.25) for colorectal cancer.
We performed meta-analysis of 11 studies on
rs2470890 which provided an OR of 1.11 (95 % CI 0.96-
1.28) for the overall cancer risk (P for heterogeneity
0.09; I2 = 39 %) (Fig. 2). Egger test and the Begg’s correl-
ation method provided no statistical evidence of publica-
tion bias (P = 0.42 and P = 0.59, respectively). The
Galbraith’s test singled out the study of Anderson LN et
al. [33] as the main contributor to heterogeneity (graph
not shown). In one-way sensitivity analysis, this study
was omitted from the overall meta-analysis and the
Fig. 3 Forest plot of the remaining five CYP1A2 SNPs and cancer meta-analyses under different models of inheritance. The diamonds and horizontal
lines correspond to the study-specific odds ratio (OR) and 95 % confidence interval (CI)
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heterogeneity dropped down to 6 % (P = 0.39), with still
not significant OR of 1.06 (95 % CI, 0.94–1.19). The ef-
fect of rs2470890 polymorphism according to the
tumour site was also evaluated and was obtained non-
significant result of OR of 1.10 (95 % CI, 0.94–1.28) P
for heterogeneity = 0.51, I2 = 0.0 % for colorectal cancer
and an OR of 1.20 (95 % CI, 0.83–1.74), P for heterogen-
eity = 0.09; I2 = 65.7 % for cancer of upper aero-digestive
tract (UADT) (Table 2). Subgroups analyses by different
ethnicity showed a significant association between
rs2470890 polymorphism and cancer for Mixed popula-
tion OR = 1.44; 95 % CI 1.16–1.80; I2 = 0.0 %, P = 0.41,
while not among Caucasians (OR = 1.07; 95 % CI 0.96–
1.20; I2 = 0.0 %, P = 0.41) nor Asians (OR = 0.77; 95 % CI
0.37–1.64; I2 = 55.4 %, P = 0.13).
Results of the remaining three SNPs of CYP1A2 are
presented in the Fig. 3 and the Table 2. Absence of sig-
nificant association with overall risk of cancer was re-
ported. Only for rs2472304 we rendered an OR of 0.72
(95 % CI 0.52–0.99) I2 = 0.0 %, P = 0.61 for Caucasians,
when doing a subgroup analyses on ethnicity. No evi-
dence of significant heterogeneity was detected (data not
shown).
When the meta-analyses were performed excluding
small sample size studies for all examined SNPs, there
were still no significant results obtained for the associ-
ation between CYP1A2 SNPs and cancer risk (Table 2).
Discussion
The current meta-analysis included 71 studies with more
than 47,000 cancer cases and 58,000 controls, detailing
on all the CYP1A2 gene polymorphisms and risk of can-
cer, shows no significant effect of investigated CYP1A2
SNPs on cancer overall risk under various genetic
models. Meta-analysis is a common tool for summariz-
ing different studies to resolve the problem of small size
statistical power and discrepancy in genetic association
studies [85] and also it provides more reliable results
than a single case-control study. To the best of our
knowledge, this is the largest and most comprehensive
meta-analysis on CYP1A2 SNPs and cancer performed
so far. Several previous meta-analyses have been re-
ported on the association between CYP1A2 gene poly-
morphisms and risk of cancer [86–95]. Deng et al. [87]
reported no association between CYP1A2 rs762551 poly-
morphism and lung cancer risk by including 1675 cases
and 2393 controls. In the paper of Xue et al. [94], com-
bined mutational homozygous and wild type homozy-
gous genotype compared with mutational heterozygous
genotype, had protective effect against gastric cancer by
including 383 cases and 1229 controls. Wen-Xia Sun et
al. [91] reported a significant protective effect of homo-
zygous mutant of rs762551 CYP1A2 SNP on bladder
cancer in Caucasian population. Based on 19 studies,
Wang et al. [93] found a borderline significantly in-
creased risk of overall cancer among homozygous mu-
tant of CYP1A2 rs762551, mainly in Caucasians. The
meta-analysis of 46 case-control studies by Tian et al.
[92] suggested that the wild-type allele of CYP1A2
rs762551 polymorphism might be associated with breast
and ovarian cancer risk, especially among Caucasians.
These inconclusive results could be explained by differ-
ences in study design, sample size, ethnicity, and cancer
subtypes included.
The CYP1A2 gene is a member of the CYP1 family
and is involved in metabolism of carcinogens and
Fig. 4 Funnel plot for publication bias for studies with CYP1A2 rs762551. Each point represents an individual study for the indicated association
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Table 2 Subgroup meta-analyses of CYP1A2 SNPs and cancer risk according to study design, ethnicity and tumour site
Number cases/controls Recessive model
Exposed Not exposed OR° 95 % CI° I2 (%) P value for
heterogeneity
rs762551 3373/4006 29,808/36,562 1.03 0.96–1.12 50.4 <0.01
Study design
Hospital based 1048/1110 8289/8482 1.03 0.88–1.20 60.3 <0.01
Population based 2314/2869 21,326/27,820 1.05 0.96–1.15 41.8 <0.01
Study sample size
Large 2883/3387 27,381/32,680 1.02 0.94–1.11 55.9 <0.01
Small 490/619 2427/3882 1.09 0.90–1.32 36.0 0.05
Ethnicity
Asian 348/414 2539/2874 0.95 0.72–1.27 54.6 0.02
Caucasian 2132/2600 18,305/23,388 1.03 0.94–1.13 42.4 <0.01
Mixed 893/992 8964/10,300 1.05 0.89–1.25 62.8 <0.01
Tumour site
Bladder 392/436 3038/2806 0.84 0.70–1.01 28.5 0.23
Breast 1097/1280 10,285/13,269 1.17 0.94–1.45 79.2 <0.01
Colorectum 803/934 7755/9199 1.03 0.93–1.14 0.0 0.56
Endometrium 258/391 1095/1898 1.06 0.87–1.30 0.0 0.85
Liver 12/26 235/330 0.63 0.30–1.32 5.0 0.31
Lung 221/265 1536/2446 1.20 0.87–1.64 58.9 0.01
Ovaries 27/34 349/478 1.31 0.33–5.19 80.3 0.01
Pancreas 107/142 1296/1656 1.04 0.80–1.36 0.0 0.87
Stomach 46/141 425/1258 0.85 0.59–1.21 0.0 0.45
UADT 186/192 1670/1631 0.97 0.73–1.29 29.9 0.23
Number cases/controls Dominant model
Exposed Not exposed OR 95 % CI I2 (%) P value for
heterogeneity
rs2069514 1229/1373 3333/5026 0.99 0.81–1.21 60.0 <0.01
Study design
Hospital based 758/783 1727/2329 1.01 0.73–1.40 73.7 <0.01
Population based 471/590 1606/2697 0.94 0.78–1.14 10.6 0.35
Study sample size
Large 969/1085 2691/3736 0.97 0.86–1.09 0.0 0.89
Small 260/288 642/1290 1.18 0.65–2.11 81.1 <0.01
Ethnicity
Asian 1093/1235 1297/1388 0.96 0.86–1.07 0.0 0.86
Caucasian 136/138 2036/3638 1.16 0.63–2.14 75.7 <0.01
Tumour site
Bladder 236/237 352/326 0.92 0.73–1.17 0.0 0.81
Colorectum 447/458 836/847 0.96 0.65–1.43 53.2 0.07
Liver 315/409 324/393 0.94 0.76–1.15 0.0 0.68
Lung 211/219 1397/1881 1.16 0.68–1.99 76.3 <0.01
Number cases/controls Dominant model
Exposed Not exposed OR 95 % CI I2 (%) P value for
heterogeneity
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Table 2 Subgroup meta-analyses of CYP1A2 SNPs and cancer risk according to study design, ethnicity and tumour site (Continued)
rs2069526 139/202 1486/2144 0.94 0.70–1.26 20.7 0.27
Study design
Hospital based 35/78 706/1236 0.89 0.47–1.72 53.9 0.09
Population based 104/124 780/908 0.94 0.71–1.25 0.0 0.59
Study sample size
Large 121/151 1137/1181 0.85 0.56–1.28 49.4 0.12
Small 18/51 349/963 1.29 0.71–2.35 0.0 0.89
Ethnicity
Caucasian 139/202 1486/2144 0.94 0.70–1.26 20.7 0.27
Tumour site
Colorectum 74/93 737/788 0.91 0.66–1.26 0.0 0.40
Lung 60/75 676/811 0.90 0.47–1.71 55.4 0.08
Number cases/controls Recessive model
Exposed Not exposed OR 95 % CI I2 (%) P value for
heterogeneity
rs2470890 1106/1187 4559/5538 1.11 0.96–1.28 39.0 0.09
Study design
Hospital based 429/480 2594/3069 1.10 0.95–1.27 0.0 0.46
Population based 655/670 1783/2219 1.09 0.80–1.50 70.5 0.02
Study sample size
Large 1077/1043 4390/4714 1.11 0.94–1.30 50.9 0.04
Small 29/144 169/824 1.07 0.69–1.66 0.0 0.85
Ethnicity
Asian 28/42 873/975 0.77 0.37–1.64 55.4 0.13
Caucasian 863/957 2904/3525 1.07 0.96–1.20 0.0 0.47
Mixed 215/188 782/1038 1.44 1.16–1.80 0.0 0.41
Tumour site
Breast 222/189 866/1025 1.17 0.65–2.08 73.4 0.05
Colorectum 500/509 866/929 1.10 0.94–1.28 0.0 0.51
Lung 48/77 348/520 0.92 0.63–1.37 0.0 0.47
UADT 294/262 1535/1528 1.20 0.83–1.74 65.7 0.09
Number cases/controls Recessive model
Exposed Not exposed OR 95 % CI I2 (%) P value for
heterogeneity
rs2472304 127/172 975/1107 0.84 0.64–1.09 0.0 0.43
Study design
Population based 85/120 261/395 0.82 0.51–1.30 40.4 0.20
Study sample size
Large 112/136 878/846 0.79 0.59–1.05 0.0 0.41
Ethnicity
Caucasian 92/121 346/383 0.72 0.52–0.99 0.0 0.61
Tumour site
Breast 42/52 714/712 0.94 0.61–1.45 0.0 0.43
Number cases/controls Dominant model
Exposed Not exposed OR 95 % CI I2 (%) P value for
heterogeneity
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estrogens. In particular, it plays an essential role in the
metabolic activation of pro-carcinogens, such as polycyc-
lic aromatic hydrocarbons (PAHs) and heterocyclic aro-
matic amines (HAA) [93]. Therefore, increased levels of
this enzyme could explain the association with increased
risk for cancer [16]. The wild genotype of CYP1A2*1 F
represents a highly inducible genotype, and this high
CYP1A2 activity may increase the hydroxylated forms
as proximate carcinogens, from HCAs and aryl-
amines [29].
In our meta-analyses, we showed that none of the in-
vestigated CYP1A2 polymorphisms were significantly as-
sociated with overall risk of cancer at various sites.
These results confirm the findings of a recent meta-
analysis from Li Zhenzhen et al. [95] where was reported
no significant associations with cancer risk in any gen-
etic model (allele contrast, codominant, dominant, or re-
cessive model) in terms of rs2069514 and rs3569413.
For rs762551, they found that carriers of C-allele have
an increased overall risk of developing cancer in allele
genetic model (C-allele vs. A-allele) while not in other
models. Their further subgroup analyses demonstrated
that rs762551 polymorphism was associated with an in-
creased risk of cancer in Caucasians under dominant
model, while we investigated rs762551 under recessive
model and did not obtain significant association. More-
over, their meta-analysis included only 37 case-control
studies of rs762551 involving 16,825 cancer cases and
21,513 controls. Our meta-analysis may be the most
comprehensive meta-analysis of the relationship between
the CYP1A2 rs762551 polymorphisms and the risk of
cancer, to date.
When stratifying according to tumour site, our results
showed a borderline not significant OR of 0.84 (95 % CI,
0.70–1.01) for bladder cancer for those homozygous mu-
tant of rs762551 with total of 3430 cases and 3242 con-
trols included (Table 2), thus confronting the previous
evidence from Wen-Xia Sun et al. [91] that reported an
OR = 0.79 (95 % CI 0.66–0.94) from 2415 cases and
2208 controls, and suggesting that on even bigger num-
ber of subjects investigated, this significance might dis-
appear. Pavanello et al. [96] stressed that polymorphisms
of rs762551 might be the crucial modulating factor along
the continuum from the exposure to relevant environ-
mental and occupational factors, in increased CYP1A2
activity of smokers measured by the urinary caffeine
metabolic ratio.
We also found a significant decreased risk for bladder
cancer for mutant carriers of rs762551 among the
hospital-based population. Hospital-based studies have
certain biases since those controls may have some be-
nign diseases which can progress and also may not be
representative of the general population. Using a
population-based control would reduce the chance of
bias in these studies.
In one recent meta-analysis by Zhi-Bin Bu et al. [86]
on the association between CYP1A2 rs762551,
rs2069514, rs2069526, and rs2470890 polymorphisms
and lung cancer risk, there was no evidence of signifi-
cant association between lung cancer risk and CYP1A2
rs2069514, s2470890, and rs2069526 polymorphisms.
They found increased lung cancer risk for rs762551
polymorphism in Caucasians from 3 studies, while in
our analysis there was no such connection on a bigger
sample of studies [24, 26–28, 30–32].
Lastly, when stratifying our results for breast and colo-
rectal cancer, we did not report any significant associ-
ation between rs762551 and these cancers, thus
confirming previous meta-analyses of Li-Xin Qiu et al.
[90] on breast and Xiao-Feng He et al. [88] on colorectal
cancer risk. Other meta-analysis by Jianbing Hu et al.
[89] also suggested that CYP1A2 rs762551 polymorph-
ism was not a risk factor for colorectal cancer suscepti-
bility, since no association was detected after all studies
Table 2 Subgroup meta-analyses of CYP1A2 SNPs and cancer risk according to study design, ethnicity and tumour site (Continued)
rs35694136 439/419 839/1183 1.37 0.78–2.42 89.0 <0.01
Study design
Hospital based 290/263 373/379 1.46 0.56–3.77 92.7 <0.01
Population based 149/156 466/804 1.28 0.77–2.13 68.4 0.08
Study sample size
Large 290/319 632/970 1.11 0.75–1.64 69.8 0.04
Small 149/100 207/213 1.78 0.37–8.60 94.6 <0.01
Ethnicity
Caucasian 255/241 635/898 1.04 0.70–1.53 62.0 0.05
Mixed 184/178 204/285 2.73 0.28–27.09 97.3 <0.01
Tumour site
Lung 149/156 466/804 1.28 0.77–2.13 68.4 0.08
Statistically significant ORs are presented in bold. °OR (95 % CI) Odds Ratio and 95 % Confidence Interval
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were pooled together nor in a subgroup analysis by eth-
nicity or source of controls, in all genetic models. The
influence of the different CYP1A2 SNPs might be
camouflaged by the presence of some yet unidentified
causal genes involved in many other types of cancer.
When stratifying the results according to ethnicity, the
protective effect of rs2472304 in our study was restricted
only to Caucasians, while for rs2470890, we noticed an in-
creased risk among a mixed population. A possible ex-
planation for these results could be that the same
polymorphisms may play different roles in cancer suscep-
tibility in different ethnic populations as well as different
tumour positions, due to a difference in genetic back-
grounds, the environment they live in, lifestyle and migra-
tions, which all may have a critical role in cancer
pathogenesis [97]. Also, some low penetrance genetic ef-
fects of single polymorphism could be determined by their
interaction with other polymorphisms and/or a specific
environmental exposure.
No other relevant results were reported for the
remaining SNPs, however there were available only few
studies regarding these associations, involving relatively
small number of participants.
In interpreting the results, some limitations of our study
should be considered. Firstly, only published studies were
included, so there was space for publication bias, which in
fact was confirmed by formal statistical tests. Secondly,
the study size for most of the CYP1A2 polymorphisms
was limited to perform any meaningful subgroup analyses.
Thirdly, it would have been valuable to stratify the results
according to environmental effect modifiers, though this
was not possible, as the original data sets were not avail-
able. Indeed, due to lack of access to original data used in
included studies, our meta-analyses are based on the un-
adjusted data, so the effects might be confounded or
modified by relevant covariates. Fourthly, beside
breast cancer, there are no genome-wide association
studies of the effects of CYP1A2 polymorphisms on
cancer risk. We were able to include only one breast
cancer GWAS into our analyses, therefore our results
might be affected by additional publication bias.
Despite these limitations, our meta-analyses also have
some advantages. First, the statistical power of the ana-
lyses was noticeably increased as a huge number of cases
and controls were pooled from different studies and has
more statistical powerful than any single case-control
study. Secondly, in our analyses, we included more stud-
ies than any previously published meta-analysis on the
association between CYP1A2 polymorphism and cancer
risks and investigated 6 different CYP1A2 SNPs.
Conclusions
In conclusion, our meta-analysis suggests that investi-
gated CYP1A2 polymorphisms are not associated with
cancer susceptibility under various genetic models. In
order to reach a more definitive conclusion, there is a
necessity for further gene-gene and gene-environment
interaction studies to be conducted on different popula-
tions and larger sample size, for diverse CYP1A2 SNPs.
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